Cayman Lrrk2-In-1; Purity- Greater Than Or Equal To 95%; Size- 1

ZLY032 is a dual agonist of free fatty acid receptor 1 (FFAR1/GPR40; EC₅₀ = 68 nM in a FLIPR assay) and peroxisome proliferator-activated receptor δ (PPARδ; EC₅₀ = 102 nM in a reporter assay). It is selective for FFAR1 and PPARδ over PPARα and PPARγ (EC₅₀s = >10 µM for both). ZLY032 (40 mg/kg, twice per day) reduces blood glucose levels in an oral glucose tolerance test and decreases plasma total cholesterol and triglyceride levels in the ob/ob mouse model of metabolic disease. It reduces hepatic steatosis and plasma alanine transaminase (ALT) and aspartate aminotransferase (AST) levels in a mouse model of non-alcoholic steatohepatitis (NASH) induced by a methionine and choline-deficient diet at the same dose.

WARNING This product is not for human or veterinary use.